| Name | Title | Contact Details |
|---|
RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body`s own cells. By targeting specific genes, RaNA`s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease. The company`s leadership leverages preeminent founders and advisors in the field, and the strength of its fundamental patents, technology, and know-how that underlie the discovery and development of therapeutics that selectively activate RNA. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases.
NeuroVasx is a Maple Grove, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Buckeye Pharmaceuticals is a Beachwood, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Epic Health Services was founded in 2001 and has since become a leading provider of pediatric and adult care services, including skilled nursing, therapy, personal care and behavioral health nursing. With 31 offices located in Texas, New Jersey, Pennsylvania, Massachusetts and Delaware, as well as 11 outpatient pediatric therapy clinics in Texas, the company is committed to providing the highest quality care delivered with compassion and extraordinary service.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.